Oramed Pharmaceuticals Inc expected to post a loss of 2 cents a share - Earnings Preview
05/03/2025 21:02
Oramed Pharmaceuticals Inc ORMP.OQ ORMP.O is expected to show no change in quarterly revenue when it reports results on March 7 (estimated) for the period ending December 31 2024 LSEG's mean analyst estimate for Oramed Pharmaceuticals Inc is for a loss of 2 cents per share. The one available analyst rating on the shares is "hold". The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Oramed Pharmaceuticals Inc is $3.25, above its last closing price of $2.14. This summary was machine generated March 5 at 21:02 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Oramed Pharmaceuticals
See all newsBrief: Nano Dimension Appoints Nadav Kidron To Board Of Directors To Chair Strategy And Capital Allocation Committee
Oramed Pharmaceuticals Inc expected to post earnings of 43 cents a share - Earnings Preview
Brief: Oramed And Lifeward Announce Strategic Transaction
Brief: Oramed Receives $18 Million Payment From Scilex Holdings
Brief: Oramed Reports Fiscal Third Quarter 2025 Financial Results